Li Yun, Yu Ping, Wang Ran
Department of Pharmacy, Nanjing Lishui People's Hospitial (Zhongda Hospital Lishui Branch), Southeast University, Nanjing, China.
Front Pharmacol. 2025 May 21;16:1545614. doi: 10.3389/fphar.2025.1545614. eCollection 2025.
Anaplastic lymphoma kinase (ALK) inhibitor alectinib has demonstrated significant potential in treating non-small cell lung cancer (NSCLC); however, its adverse effects remain a notable challenge for healthcare professionals. This report examines the case of a 79-year-old female lung cancer patient who presented with persistent colic in the left abdomen 10 months after initiating alectinib treatment. Upon admission, abdominal computed tomography revealed mild thickening of the descending colon wall, accompanied by free gas and surrounding exudation, leading to a diagnosis of descending colon perforation. After excluding alternative causes of gastrointestinal perforation, the condition was attributed to a severe adverse reaction associated with alectinib. While alectinib has been reported to cause serious gastrointestinal perforations, the underlying mechanism remains unclear and warrants further clinical investigation. Clinicians should be vigilant in recognizing and promptly managing this potential complication during alectinib therapy.
间变性淋巴瘤激酶（ALK）抑制剂阿来替尼在治疗非小细胞肺癌（NSCLC）方面已显示出显著潜力；然而，其不良反应对医疗保健专业人员来说仍然是一个显著挑战。本报告探讨了一名79岁女性肺癌患者的病例，该患者在开始使用阿来替尼治疗10个月后出现左腹部持续性绞痛。入院时，腹部计算机断层扫描显示降结肠壁轻度增厚，伴有游离气体和周围渗出物，导致诊断为降结肠穿孔。在排除胃肠道穿孔的其他原因后，该病症归因于与阿来替尼相关的严重不良反应。虽然已有报道阿来替尼会导致严重的胃肠道穿孔，但其潜在机制仍不清楚，值得进一步临床研究。临床医生在阿来替尼治疗期间应警惕识别并及时处理这种潜在并发症。
